Research Status of TPO/c-MPL Signaling Pathway in Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2021.04.054
- Author:
Nan WANG
1
;
Hai-Yan ZHU
2
Author Information
1. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
2. Department of Hematology, The First Medical Center, Chinese PLA General Hospital, Beijing 100853, China,E-mail: hyzhu1975@163.com.
- Publication Type:Journal Article
- MeSH:
Humans;
Leukemia, Myeloid, Acute;
Neoplasm Proteins;
Proto-Oncogene Proteins/metabolism*;
Receptors, Cytokine;
Receptors, Thrombopoietin;
Signal Transduction;
Thrombopoietin
- From:
Journal of Experimental Hematology
2021;29(4):1351-1354
- CountryChina
- Language:Chinese
-
Abstract:
Thrombopoietin (TPO) can activate hematopoietic cell proliferation by its receptor c-MPL mediated downstream pathways and induce the generation of megakaryocyte. In recent years, domestic and foreign researches have confirmed that TPO/ c-MPL pathway also plays an important role in the self-renewal and quiescence of leukemia stem cell, and its expression in acute myeloid leukemia (AML) also indicates the chemotherapy resistance and poor prognosis. In this article, the research progress of the roles of TPO/c-MPL pathway in chemotherapy resistance, prognosis of AML patients, and the application of TPO/ c-MPL receptor agonists in AML were summarized briefly.
